Substituted azaindoleoxoacetic piperazine derivatives with protease inhibitors

Abstract

This invention provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the invention is concerned with azaindoleoxoacetyl piperazine derivatives having the Formula I: wherein Q is These compounds possess unique antiviral activity, whether used alone or in combination with other antivirals, antiinfectives, immunomodulators or HIV entry inhibitors. More particularly, the present invention relates to the treatment of HIV and AIDS.

What is claimed is: 
     
         1 . A compound of Formula I, including pharmaceutically acceptable salts thereof, 
       
         
           
           
               
               
           
         
         wherein: 
         Q is: 
       
       
         
           
           
               
               
           
         
         R 1  is hydrogen; 
         R 2  is hydrogen, halogen, or methoxy; 
         R 3  is hydrogen; 
         R 4  is a heteroaryl group, wherein said heteroaryl group is optionally substituted with one to three different substituents selected from group F; 
         wherein - - represents a carbon-carbon bond or does not exist; 
         R 5  is hydrogen; 
         R 6  does not exist; 
         m is 2; 
         —W— is 
       
       
         
           
           
               
               
           
         
         R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16  are each independently selected from the group consisting of hydrogen and (C 1-6 )alkyl; 
         A is phenyl, furan or pyridine; 
         F is selected from the group consisting of —(C 1-6 )alkyl, hydroxy, —(C 1-6 )alkoxy, —C(O)R 57 , —NR 42 C(O)—(C 1-6 )alkyl, —NR 42 S(O) 2 —(C 1-6 )alkyl, —NR 42 R 43 , and —COOR 54 ; 
         R 42  and R 43  are independently selected from hydrogen and (C 1-6 )alkyl; 
         R 54  is selected from the group consisting of hydrogen and (C 1-6 )alkyl; and 
         R 57  is selected from the group consisting of hydrogen and (C 1-6 )alkyl. 
       
     
     
         2 . The compound of  claim 1 , wherein said heteroaryl group is selected from the group consisting of thiazole, pyridazine, pyrazole, imidazole, furyl, thienyl, oxazole, oxadiazole, pyrimidine, pyrazole, tetrazole and pyridyl. 
     
     
         3 . A compound of Formula I, including pharmaceutically acceptable salts thereof, 
       
         
           
           
               
               
           
         
         wherein: 
         Q is: 
       
       
         
           
           
               
               
           
         
         R 1  is hydrogen; 
         R 2  is hydrogen, halogen, or methoxy; 
         R 3  is hydrogen; 
         R 4  is a heteroaryl group, wherein said heteroaryl group is selected from the group consisting of: 
       
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         wherein X 2  represents the point of attachment; 
         wherein - - represents a carbon-carbon bond or does not exist; 
         R 5  is hydrogen; 
         R 6  does not exist; 
         m is 2; 
         —W— is 
       
       
         
           
           
               
               
           
         
         A is phenyl, furan or pyridine; and 
         R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , are each independently selected from the group consisting of hydrogen and (C 1-6 )alkyl.